Bafiertam ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	3

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04925778 (ClinicalTrials.gov)	June 30, 2021	8/6/2021	Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate	An Open-label, Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® (Monomethyl Fumarate) From Dimethyl Fumarate (PERSIST)	Relapsing Remitting Multiple Sclerosis	Drug: monomethyl fumarate	Banner Life Sciences LLC	NULL	Withdrawn	18 Years	N/A	All	0		NULL
2	NCT04022473 (ClinicalTrials.gov)	July 7, 2019	15/7/2019	Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers	A Randomized, Double-Blind Study to Compare Gastrointestinal Tolerability Following Oral Administration of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate) to Healthy Male and Female Volunteers	Multiple Sclerosis	Drug: Bafiertam;Drug: Tecfidera	Banner Life Sciences LLC	NULL	Completed	18 Years	65 Years	All	210	Phase 1	United States
3	NCT04570670 (ClinicalTrials.gov)	January 6, 2017	22/9/2020	Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects	A Single-Dose, Randomized, Open-Label, 2-Way Crossover, Comparative Bioavailability Study of BLS-11 (Monomethyl Fumarate) 190 mg and Tecfidera (Dimethyl Fumarate) 240 mg in Healthy Male and Female Subjects Under Fasting Conditions	Relapsing Remitting Multiple Sclerosis	Drug: monomethyl fumarate 190 mg;Drug: dimethyl fumarate 240 mg	Banner Life Sciences LLC	NULL	Completed	18 Years	55 Years	All	50	Phase 1	NULL